Eli Lilly (LLY)
1,078.78
+14.63 (1.37%)
NYSE· Last Trade: Jun 3rd, 4:29 PM EDT
Detailed Quote
| Previous Close | 1,064.15 |
|---|---|
| Open | 1,059.50 |
| Bid | 1,078.48 |
| Ask | 1,084.91 |
| Day's Range | 1,053.51 - 1,093.28 |
| 52 Week Range | 623.78 - 1,149.10 |
| Volume | 2,579,220 |
| Market Cap | 1.03T |
| PE Ratio (TTM) | 47.01 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.64%) |
| 1 Month Average Volume | 3,194,999 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Can any company pose a serious challenge to Eli Lilly in the weight-loss market?
Via The Motley Fool · June 3, 2026
There is light at the end of the tunnel.
Via The Motley Fool · June 3, 2026
SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.
Via The Motley Fool · June 3, 2026
Eli Lilly & Co. (NYSE:LLY) Ranks as a Textbook Growth Stockchartmill.com
Via Chartmill · June 1, 2026
This particular sector may suit cautious and aggressive investors.
Via The Motley Fool · June 3, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 3, 2026
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape
Via TheNewswire.com · June 3, 2026
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.
Via The Motley Fool · June 3, 2026
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.
Via The Motley Fool · June 3, 2026
Eli Lilly's pipeline is an embarrassment of riches.
Via The Motley Fool · June 3, 2026
It is finally bouncing back after several challenging years.
Via The Motley Fool · June 3, 2026
Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact.
Via The Motley Fool · June 2, 2026
Huang has lofty expectations for Marvell Technology.
Via The Motley Fool · June 2, 2026
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.
Via MarketBeat · June 2, 2026
An upcoming trial result could change how investors think about the weight-loss drug market.
Via The Motley Fool · June 2, 2026
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
Via The Motley Fool · June 2, 2026
Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors.
Via The Motley Fool · June 2, 2026
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.
Via The Motley Fool · June 1, 2026
Micron Technology just became the 12th-biggest company in the world, bigger than Berkshire Hathaway. UBS sees another 56% upside as June 24 earnings near.
Via Benzinga · June 1, 2026
David Ricks was addressing the pharmaceutical titan's latest hot product.
Via The Motley Fool · June 1, 2026

Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.
Via Benzinga · June 1, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · June 1, 2026

Lilly shares soared more than 18% in May.
Via The Motley Fool · June 1, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via StockStory · June 1, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Via StockStory · May 31, 2026